Stockreport

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

PRANA BIOTECH  (PRAN) 
US:NASDAQ Investor Relations: pranabio.com/investors
PDF Highlights: Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial Evidence sup [Read more]